Latest News

Omnicell (OMCL) just rolled out Titan XT, a new enterprise level automated dispensing system built on its OmniSphere cloud platform, and the launch is already reshaping how investors think about the stock. See our latest analysis for Omnicell. The launch of Titan XT coincides with Omnicell’s 30 day share price return of 30.11 percent and 90 day share price return of 51.10 percent, which signal rapidly building momentum. However, the 5 year total shareholder return of negative 60.02 percent...

ABM Industries (ABM) slid after its latest earnings update, as a headline miss on expectations and cautious commentary on margins and the WGNSTAR acquisition overshadowed decent revenue growth and a fresh dividend increase. See our latest analysis for ABM Industries. The latest pullback, including a 1 day share price return of minus 2.99% and year to date share price return of minus 17.51%, suggests sentiment has cooled despite solid earnings recovery, dividend growth and ongoing buybacks...

Hecla Mining recently hit a new 52-week high after reporting record Q3 2025 revenue, earnings, and cash flow, supported by very large year-to-date silver price gains and reduced leverage. The company’s addition to the S&P MidCap 400 Index and progress on projects such as Polaris and Midas highlight growing operational scale and exploration depth that could reshape how investors view its silver-focused portfolio. We’ll now examine how Hecla’s record earnings and S&P MidCap 400 inclusion may...

On December 18, 2025, VeriSign’s Executive Chairman, President, and CEO D Bidzos sold 9,000 company shares, contributing to a year of substantial insider selling highlighted in recent SEC filings. These transactions, set against VeriSign’s role in operating critical internet infrastructure, draw attention to how leadership’s trading activity aligns with its long-term outlook on the core domain registry business. We’ll now explore how this pattern of insider selling, particularly by the CEO,...

Vodafone Group (LSE:VOD) has quietly turned into one of the U.K. market’s stronger rebound stories, with the share price up about 7% this month and roughly 15% over the past 3 months. See our latest analysis for Vodafone Group. Zooming out, Vodafone’s recent 7.29% 1 month share price return and 40.21% year to date share price return suggest momentum is rebuilding, while a 52.41% one year total shareholder return points to investors re-rating the recovery story. If Vodafone’s turnaround has...

Cintas Corporation ( NASDAQ:CTAS ) came out with its second-quarter results last week, and we wanted to see how the...

Earlier this month, Talen Energy reshaped its leadership structure by appointing former CFO Terry L. Nutt as President and naming Cole Muller as Chief Financial Officer, alongside a series of senior operational and development role changes to support its evolving power and infrastructure business. The extensive reallocation of responsibilities, from nuclear oversight and fleet operations to new generation asset development and data center strategy, signals a concerted push to align...

Shanghai Electric has recently broken ground on the Euphrates Combined Cycle Expansion Project in Iraq, upgrading power plants across four governorates by converting simple-cycle units into combined-cycle systems to add 625 megawatts of capacity and generate an extra 5 billion kilowatt-hours annually without more fuel. The project, which fully deploys Chinese-designed core equipment and standards in one of Iraq’s first such combined-cycle expansions, strengthens Shanghai Electric’s role in...

Etsy, Inc. recently announced a new US$750 million share repurchase authorization, lifting its total approved buyback capacity to nearly US$1 billion and confirming Fred Wilson will become Lead Independent Director in January 2026 alongside a planned CEO transition. The combination of substantial buybacks and enhanced board oversight highlights Etsy’s emphasis on capital return and governance as it confronts slowing gross merchandise sales and buyer engagement. Now we’ll examine how Etsy’s...

Earlier this month, Citizens Financial Group reported that analysts expect its fiscal fourth-quarter 2025 diluted EPS to reach US$1.12, implying a very large year-over-year profit increase, after the bank topped Wall Street earnings estimates in each of the previous four quarters. The bank’s performance has been underpinned by expansion in its private bank and wealth franchise, strong capital markets activity, and tighter cost control supported by technology and private banking investments...

In December 2025, Lingbao Gold Group announced a series of boardroom changes, including the resignation of an independent non-executive director and the replacement of an executive director with a new appointee linked to the controlling shareholder. The rapid reshaping of its board and key committees, including leadership of the remuneration and strategy functions, spotlights governance, succession, and influence at the company. We will now explore how this shift in board independence and...

Earlier this month, U.S. President Donald Trump signed an executive order reclassifying cannabis from Schedule I to Schedule III, while Canopy Growth reported narrowing adjusted EBITDA losses, eliminated going‑concern warnings, and prepaid US$50 million on a senior secured term loan to cut interest costs. At the same time, Canopy Growth advanced its Canadian footprint with an agreement to acquire Quebec-based MTL Cannabis and continued to benefit from a more supportive U.S. regulatory...

Earlier this year, Regencell Bioscience Holdings disclosed that the US Department of Justice had launched an investigation into trading of its shares and requested extensive operational, financial and accounting records, prompting the company to warn of potentially significant legal costs and penalties. The subsequent involvement of law firm Bronstein, Gewirtz & Grossman, LLC, which is examining potential claims on behalf of Regencell purchasers, adds another layer of legal uncertainty...

In recent days, Procter & Gamble’s Pantene brand expanded its influencer push by launching a limited‑edition “As seen in Alix’s Shower” Abundant & Strong kit with creator Alix Earle, while the company also confirmed the planned 2026 retirement of long‑time Health Care CEO Jennifer Davis. Together with prior announcements on European logistics expansion and portfolio pruning, these moves highlight how P&G is refining its brand reach while tightening its operational footprint. We’ll now...

Vera Therapeutics (VERA) has been on investors’ radar after upbeat analyst reports flagged two key drivers: rising revenue expectations for kidney drug candidate atacicept and a cash boost from a recent follow on equity raise. See our latest analysis for Vera Therapeutics. The upbeat story around atacicept and the recent equity raise is already showing up in the tape, with a roughly 80 percent 1 month share price return and a near doubling over three months. This builds on a strong 3 year...

Innoviva, Inc. recently received US FDA approval for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic to treat uncomplicated urogenital gonorrhea in adults and pediatric patients. This marks one of the first new FDA-approved treatments for gonorrhea in nearly twenty years, underscoring Innoviva’s role in addressing antibiotic resistance and unmet infectious disease needs. We’ll now explore how bringing a first-in-class, single-dose oral treatment for gonorrhea affects...

As the Canadian market navigates a noisy end to 2025 with a constructive outlook for 2026, investors are keenly observing the potential shifts in market leadership and portfolio positioning. In this context, penny stocks—often representing smaller or newer companies—offer an intriguing mix of affordability and growth potential when backed by strong financials. Despite being seen as a relic of past trading days, these stocks continue to provide opportunities for investors looking to uncover...

For many, the main point of investing is to generate higher returns than the overall market. But every investor is...

Core & Main (CNM) just checked several key boxes in its latest earnings update, pairing steady third quarter growth with a clear commitment to acquisitions, share buybacks and disciplined capital allocation. See our latest analysis for Core & Main. The stock has cooled slightly after the earnings pop, with a 1 month share price return of 18.01% and a 3 year total shareholder return of 181.16%. This suggests momentum is still firmly on Core & Main’s side. If this kind of steady execution...

Kinder Morgan (KMI) just tightened the picture for income investors, issuing fresh 2025 and 2026 profit guidance alongside plans for a higher 2026 dividend that extends its long running payout growth streak. See our latest analysis for Kinder Morgan. At a recent share price of $26.49, Kinder Morgan’s year to date share price return of minus 5.76 percent contrasts with its 5 year total shareholder return of 159.74 percent. This suggests that longer term income focused momentum remains firmly...

Institutional Buying and Upgraded Outlook Draw Investor Focus Laureate Education (LAUR) is back on investors radar after Formula Growth snapped up 111,000 shares, just as the company raised its full year outlook and expanded its buyback program. See our latest analysis for Laureate Education. The upgraded outlook, stronger enrollment trends, and larger buyback program appear to be feeding real momentum, with a roughly 86 percent year to date share price return and a 3 year total shareholder...

Elanco Animal Health recently received conditional FDA approval for Credelio Quattro-CA1, the first companion animal treatment for New World screwworm, while also advancing Befrena toward USDA approval and restructuring operations to cut costs and expand innovation capacity in the United States. Together with plans for tuck-in M&A and expanded monoclonal antibody manufacturing, these moves suggest Elanco is reshaping its pet health portfolio around higher-value, innovation-focused...

Madrigal Pharmaceuticals recently reported positive two-year Phase 3 MAESTRO-NAFLD-1 data for REZDIFFRA in compensated MASH cirrhosis and announced equity inducement awards for new employees, while also appointing industry veteran Rita Thakkar as its next Senior Vice President and Chief Accounting Officer effective January 12, 2026. These developments strengthen confidence in REZDIFFRA’s clinical profile and Madrigal’s financial governance, potentially reinforcing the company’s positioning...

Earlier this month, Pulse Biosciences received FDA Investigational Device Exemption approval to begin its NANOPULSE-AF clinical study of the nPulse Cardiac Catheter Ablation System in up to 145 patients with drug-resistant paroxysmal atrial fibrillation across as many as 30 global sites. This milestone, supported by ongoing European feasibility experience with 150 patients, moves the company’s nsPFA cardiac platform into a pivotal phase of clinical validation with potential implications for...